Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 2/2006

01-04-2006

ESUR guidelines on contrast media

Authors: H. S. Thomsen, S. K. Morcos

Published in: Abdominal Radiology | Issue 2/2006

Login to get access

Abstract

Since 1996 the Contrast Media Safety Committee of the European Society of Urogenital Radiology has released 15 guidelines regarding safety in relation to the use of radiographic, ultrasonographic, and magnetic resonance contrast media. The guidelines have been well received by the radiologic community in Europe and all over the world and comprise current standards for good practice at many institutions. The present report is an overview of the work accomplished by the European Society of Urogenital Radiology over the past 8 years. The committee has covered renal and nonrenal adverse events and other aspects of contrast media.
Literature
1.
Morcos SK, Thomsen HS, Webb JAW, Members of Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Contrast media induced nephrotoxicity: a consensus report. Eur Radiol 1999;9:1602–1613PubMedCrossRef
2.
Hou SH, Bushinsky DA, Wish JB, et al. Hospital acquired renal insufficiency: a prospective study. Am J Med 1983;74:243–248PubMedCrossRef
3.
4.
5.
Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration with 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542–1548PubMedCrossRef
6.
McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997;103:368–375PubMedCrossRef
7.
Rudnik MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995;47:254–261
8.
Blaufox MD, Aurell M, Bubeck B, et al. Report of the Radionuclide in Nephrourology Committee on renal clearance. J Nucl Med 1996;37:1883–1890PubMed
9.
Bostrom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002;13:2140–2144
10.
Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999;55:1878–1884PubMedCrossRef
11.
Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 2005;15:749–754PubMedCrossRef
12.
Thomsen HS. Contrast nephropathy. In: Thomsen HS, Muller RN, Mattrey RF, eds. Trends in contrast media. Berlin: Springer-Verlag, 1999:103–116
13.
Morcos SK. Prevention of contrast media nephrotoxicity—the story so far. Clin Radiol 2004;59:381–389PubMed
14.
Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416–1420PubMed
15.
Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-aceyltylcysteine, fenoldopam and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Intervent 2002;57:279–283
16.
Mueller C, Burkle G, Buerkle HJ, et al. Prevention of contrast media-associated nephropathy. Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329–336PubMed
17.
Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003;93:c29–c34PubMedCrossRef
18.
Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomized controlled trial. JAMA 2004;291:2328–2334PubMedCrossRef
19.
Morcos SK, Thomsen HS. Webb JAW, Members of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Dialysis and contrast media. Eur Radiol 2002;12:3026–3030PubMed
20.
Dehnarts T, Keller E, Gondolf K, et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13:358–362
21.
Vogt B, Ferrari P, Schonholzer C, et al. Pre-emptive haemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111:692–698PubMedCrossRef
22.
Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003;60:176–182PubMed
23.
Huber W, Jeschke B, Kreymann B, et al. Haemodialysis of the prevention of contrast-induced nephropathy. Outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 2002;37:471–481PubMedCrossRef
24.
Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent–induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333–1340PubMedCrossRef
25.
Thomsen HS, Almén T, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002;12:2600–2605PubMed
26.
Sam AD II, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003;38:313–318PubMed
27.
Spinosa DJ, Angle JF, Hagspiel KD, et al. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 2000;11:35–43PubMed
28.
Gemmete JJ, Forauer AR, Kazanjian S, et al. Safety of large volume gadolinium angiography (abstract). J Vasc Interv Radiol 2001;12(pt 2):S 28
29.
Schenker MP, Solomon JA, Roberts DA. Gadolinium arteriography complicated by acute pancreatitis and acute renal failure (letter). J Vasc Interv Radiol 2001;12:393PubMed
30.
Terzi C, Sokmen S. Acute pancreatitis induced by magnetic-resonance-imaging contrast agent. Lancet 1999;354:1789–1790PubMedCrossRef
31.
Elmståhl B, Nyman U, Leander P, et al. Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. Acta Radiol 2004;11:1219–1228
32.
Thomsen HS, Morcos SK, and Members of Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Contrast media and metformin. Guidelines to diminish the risk of lactic acidosis in non–insulin dependent diabetics after administration of contrast media. Eur Radiol 1999;9:738–740PubMedCrossRef
33.
Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987;317:845–849PubMed
34.
Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. Radiology 1990;175:621–628PubMed
35.
Lasser EC, Berry CC, Mishkin MM, et al. Pretreatment with corticosteroids to prevent adverse reactions to non-ionic contrast media. AJR 1994;162:523–526PubMed
36.
Dawson P, Sidhu PS. Is there a role for corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents? Clin Radiol 1993;48:225–226PubMed
37.
Lasser EC. Corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents (letter). Clin Radiol 1994;49:582–583PubMed
38.
Dore C, Sidhu PS, Dawson P. Corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents (letter). Clin Radiol 1994;49:583–584
39.
Lasser EC, Berry CC. Corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents (letter). Clin Radiol 1994;49:584
40.
Dore CJ, Sidhu PS, Dawson P. Corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents (letter). Clin Radiol 1995;50:198–199PubMed
41.
Lasser EC. Corticosteroid prophylaxis in patients at increased risk of adverse reactions to intravascular contrast agents (letter). Clin Radiol 1995;50:199
42.
Seymour R, Halpin SF, Hardman JA, et al. Corticosteroid prophylaxis for patients with increased risk of adverse reactions to intravenous contrast agents: a survey of current practice in the UK. Clin Radiol 1994;49:791–795PubMed
43.
Morcos SK, Thomsen HS, Webb JAW, Contrast Media Safety Committee of the European Society of Urogenital Radiology. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol 2001;11:1720–1728PubMedCrossRef
44.
Thomsen HS, Bush WH. Treatment of the adverse effects of contrast media. Acta Radiol 1998;39:212–218PubMed
45.
Dunnick NR, Cohan RH. Cost, corticosteroids, and contrast media. AJR 1994;162:527–529PubMed
46.
Cohan RH, Ellis JH, Dunnick NR. Use of low-osmolar agents and premedication to reduce the frequency of adverse reactions to radiographic contrast media: a survey of the Society of Uroradiology. Radiology 1995;194:357–364PubMed
47.
Thomsen HS, Dorph S. High-osmolar and low-osmolar contrast media. An update on frequency of adverse drug reactions. Acta Radiol 1993;34:205–209PubMed
48.
Thomsen HS, Bush WH Jr. Adverse effects of contrast media. Incidence, prevention and management. Drug Safety 1998;19:313–324PubMedCrossRef
49.
Shehadi WH. Death following intravascular administration of contrast media. Acta Radiol Diagn 1985;26:457–461
50.
Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR 1991;157:1153–1161PubMed
51.
Gillenberger P, Halwig TM, Patterson R, et al. Emergency administration of a radiocontrast media in high risk patients. J Allergy Clin Immunol 1986;77:630–635
52.
Bush WH, McClennan BL, Swanson DP. Contrast media reactions: prediction, prevention, and treatment. Postgrad Radiol 1993;13:137–147
53.
Cohan RH, Leder RA, Ellis JH. Treatment of adverse reactions to radiographic contrast media in adults. Radiol Clin North Am 1996;34:1055–1060PubMed
54.
Emergency Cardiac Care Committee, Subcommittees of the American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care III: adult advanced cardiac life support. JAMA 1992;268:2199–2241
55.
Webb JAW, Stacul F, Thomsen HS, Morcos SK, Members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003;13:181–184PubMed
56.
Bellin M-F, Jakobsen JÅ, Tomassin I, et al, Members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Contrast medium extravasation injury: guidelines for prevention and management. Eur Radiol 2002;12:2807–2812PubMedCrossRef
57.
Molen AJvd, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 2004;14:902–906PubMed
58.
Webb JAW, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 15: 1234–1240PubMedCrossRef
59.
Morcos SK, Thomsen HS, Exley CM (2005) Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast media: interaction with other drugs and clinical tests. Eur Radiol 15:1463–1468PubMedCrossRef
60.
Jakobsen JA, Oyen R, Thomsen HS, Morcos SK (2005) Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Safety of ultrasound contrast agents. Eur Radiol 15:941–945PubMedCrossRef
61.
Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426–435PubMed
62.
Bluemke DA, Weber TM, Rubin D, et al. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 2003;228:457–464PubMed
63.
Marti-Bonmati L, Fog AF, Op de Beeck B, et al. Safety and efficacy of mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 2003;13:1685–1692PubMed
64.
Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481–488PubMed
65.
Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 1997;204:749–756PubMed
66.
Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282–291PubMedCrossRef
67.
Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003;13:2688–2698PubMedCrossRef
68.
Bellin MF, Zaim S, Auberton E, et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994;193:657–663PubMed
69.
Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SHU 555 A). J Magn Reson Imaging 2001;14:595–601PubMedCrossRef
70.
Reimer P, Balzer T. Ferucarbotran (Resovist), a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003;13:1266–1276PubMed
71.
Bellin M-F, Webb JAW, Molen AJvd, et al. (2005) Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Safety of MR liver specific contrast media. Eur Radiol 15:1607–1614PubMedCrossRef
Metadata
Title
ESUR guidelines on contrast media
Authors
H. S. Thomsen
S. K. Morcos
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2006
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-005-0380-y

Other articles of this Issue 2/2006

Abdominal Radiology 2/2006 Go to the issue

OriginalPaper

Unknown ESUR cases 2004

OriginalPaper

Functional magnetic resonance imaging in renal artery stenosis

OriginalPaper

RETRACTED ARTICLE: New horizons in genitourinary oncologic imaging

OriginalPaper

Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment

OriginalPaper

Abstracts of selected papers from the current literature

FEATURE SECTION, UROGENITAL RADIOLOGY: FUNCTIONAL IMAGING AND MORE RECENT ADVANCES, UNDER THE GUEST EDITORSHIP OF H. S. THOMSEN

Guest Editor’s Introduction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits